Products
Reslizumab was approved in the United States and EU in 2016 and in many countries in 2017 as a concentrate for the preparation of an infusion solution (Cinqaero).
Structure and properties
Reslizumab is a humanized IgG4/κ monoclonal antibody produced by biotechnological methods. The molecular mass is approximately 147 kDa.
Effects
Reslizumab (ATC R03DX08) binds with high affinity to interleukin-5 (IL-5) and inhibits interaction with its receptor on the cell surface of eosinophils. IL-5 is a cytokine responsible for eosinophil growth, differentiation, recruitment, activation and survival. By binding the antibody to IL-5, reslizumab inhibits these effects and has an anti-inflammatory effect. The half-life is 24 days.
Indications
For adjunctive treatment of eosinophilic asthma.
Dosage
According to the SmPC. The drug is usually administered as an intravenous infusion every four weeks.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
Complete data on drug-drug interactions are not available.
Adverse effects
The most common potential adverse effect in clinical trials was an increase in blood creatine phosphokinase. Reslizumab may cause hypersensitivity reactions.